Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: Data from Papua New Guinea

Bulletin of the World Health Organization

Volumn 89, Issue 3, 2011, Pages 211-220

  Davis, Wendy A ^a   Clarke, Philip M ^b   Siba, Peter M ^c   Karunajeewa, Harin A ^a   Davy, Carol ^d   Mueller, Ivo ^c   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; CHLOROQUINE; DIHYDROARTEMISININ; FERROUS SULFATE; FOLIC ACID; PARACETAMOL; PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE;

ANTIMALARIAL AGENT; CHILD HEALTH; DISEASE TREATMENT; EPIDEMIOLOGY; MALARIA; QUININE;

ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; EVENING DOSAGE; HEALTH CARE COST; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; OPEN STUDY; PAPUA NEW GUINEA; PARALLEL DESIGN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; SINGLE DRUG DOSE; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; INFANT; MALARIA, FALCIPARUM; PAPUA NEW GUINEA;

PAPUA NEW GUINEA;

ARTESUNATE; PLASMODIUM FALCIPARUM;

EID: 79952319607     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.10.084103     Document Type: Article

References (26)

1. Global Malaria Programme. World malaria report 2010. Geneva: World Health Organization; 2010.
2. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008.
3. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 2004;4:327-336. doi:10.1016/S1473-3099(04)01043-6 PMID:15172341
4. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009;22:430-435. doi:10.1097/QCO.0b013e32832f14c1 PMID:19571748
5. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002;415:680-685. doi:10.1038/415680a PMID:11832956
6. Chanda P, Masiye F, Chitah BM, Sipilanyambe N, Hawela M, Banda P et al., A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia. Malar J 2007;6:21. doi:10.1186/1475-2875-6-21 PMID:17313682
7. Coleman PG, Morel C, Shillcutt S, Goodman C, Mills AJ. A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-saharan Africa. Am J Trop Med Hyg 2004;71(Suppl):196-204. PMID:15331838
8. Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA. A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mumbai, India. J Assoc Physicians India 2003;51:877-879. PMID:14710972
9. Muheki C, McIntyre D, Barnes KI. Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa. Trop Med Int Health 2004;9:959-966. doi:10.1111/j.1365-3156.2004.01292.x PMID:15361108
10. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010;10:405-416. doi:10.1016/S1473-3099(10)70079-7 PMID:20510281
11. Baird JK. Real-world therapies and the problem of vivax malaria. N Engl J Med 2008;359:2601-2603. doi:10.1056/NEJMe0808729 PMID:19064622
12. Cattani JA, Tulloch JL, Vrbova H, Jolley D, Gibson FD, Moir JS etal. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am J Trop Med Hyg 1986;35:3-15. PMID:3511748
13. Müller I, Bockarie M, Alpers M, Smith T. The epidemiology of malaria in Papua New Guinea. Trends Parasitol 2003;19:253-259. doi:10.1016/S1471-4922(03)00091-6 PMID:12798082
14. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS et al.,A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008;359:2545-2557. doi:10.1056/NEJMoa0804915 PMID:19064624
15. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization; 2003.
16. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000;94(Suppl 1):S1-S90. doi:10.1016/S0035-9203(00)90300-6 PMID:11103309
17. Kase P. Prioritization in the Papua New Guinea health sector: progress towards a health medium-term expenditure framework. P N G Med J 2006;49:76-82. PMID:18389961
18. Fieller EC. Some problems in interval estimation. J R Stat Soc, ser B 1954;16:175-185.
19. Life tables for WHO Member States, 2008 [Internet]. Geneva: World Health Organization; 2008. Available from: http://apps.who.int/whosis/database/life/life_tables/life_tables.cfm?path=whosis [accessed 12 January 2011].
20. Cibulskis RE. Estimating the burden of malaria in Papua New Guinea: report of a technical consultation. Geneva: World Health Organization; 2008.
21. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
22. Morel CM, Lauer JA, Evans DB. Cost effectiveness analysis of strategies to combat malaria in developing countries. BMJ 2005;331:1299. doi:10.1136/bmj.38639.702384.AE PMID:16282381
23. Killeen GF, McKenzie FE, Foy BD, Schieffelin C, Billingsley PF, Beier JC. The potential impact of integrated malaria transmission control on entomologic inoculation rate in highly endemic areas. Am J Trop Med Hyg 2000;62:545-551. PMID:11289662
24. The World Bank. The world development indicators (WDI) 2010 [Internet]. Available from: http://data.worldbank.org/data-catalog/world-development-indicators/wdi-2010 [accessed 4 January 2011].
25. Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E et al., Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med Int Health 2009;14:332-337. doi:10.1111/j.1365-3156.2009.02227.x PMID:19187518
26. Kone A, van de Vegte-Bolmer M, Siebelink-Stoter R, van Gemert GJ, Dara A, Niangaly H etal. Sulfadoxine-pyrimethamine impairs Plasmodium falciparum gametocyte infectivity and Anopheles mosquito survival. Int J Parasitol 2010;40:1221-1228. doi:10.1016/j.ijpara.2010.05.004 PMID:20515695